Concepts (111)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Cerebral Hemorrhage | 6 | 2021 | 198 | 0.860 |
Why?
|
Data Interpretation, Statistical | 2 | 2019 | 329 | 0.740 |
Why?
|
Hearing Tests | 1 | 2020 | 70 | 0.680 |
Why?
|
Clinical Trials, Phase III as Topic | 2 | 2021 | 84 | 0.660 |
Why?
|
Statistics, Nonparametric | 1 | 2019 | 306 | 0.650 |
Why?
|
Presbycusis | 1 | 2020 | 84 | 0.640 |
Why?
|
Patient Reported Outcome Measures | 1 | 2019 | 114 | 0.630 |
Why?
|
Biostatistics | 1 | 2018 | 43 | 0.620 |
Why?
|
Research Design | 2 | 2022 | 729 | 0.620 |
Why?
|
Endpoint Determination | 1 | 2018 | 82 | 0.610 |
Why?
|
Antihypertensive Agents | 5 | 2021 | 498 | 0.610 |
Why?
|
Tissue Plasminogen Activator | 1 | 2017 | 296 | 0.490 |
Why?
|
Stroke | 4 | 2023 | 2163 | 0.450 |
Why?
|
Hematoma | 4 | 2020 | 47 | 0.380 |
Why?
|
Aphasia | 2 | 2023 | 119 | 0.380 |
Why?
|
Stroke Rehabilitation | 2 | 2023 | 335 | 0.320 |
Why?
|
Markov Chains | 2 | 2018 | 133 | 0.290 |
Why?
|
Psychometrics | 2 | 2020 | 514 | 0.280 |
Why?
|
Nicardipine | 3 | 2021 | 21 | 0.280 |
Why?
|
Blood Pressure | 4 | 2021 | 1451 | 0.250 |
Why?
|
Medical Futility | 1 | 2022 | 31 | 0.210 |
Why?
|
Vasospasm, Intracranial | 1 | 2021 | 16 | 0.200 |
Why?
|
Humans | 19 | 2023 | 68618 | 0.200 |
Why?
|
Surveys and Questionnaires | 2 | 2020 | 2800 | 0.190 |
Why?
|
Subarachnoid Hemorrhage | 1 | 2021 | 61 | 0.190 |
Why?
|
Transcranial Direct Current Stimulation | 1 | 2023 | 111 | 0.190 |
Why?
|
Hematoma, Subdural, Chronic | 1 | 2021 | 9 | 0.190 |
Why?
|
Leukoaraiosis | 1 | 2020 | 14 | 0.180 |
Why?
|
Aged | 9 | 2023 | 14862 | 0.170 |
Why?
|
Longitudinal Studies | 2 | 2020 | 1054 | 0.170 |
Why?
|
Factor Analysis, Statistical | 1 | 2019 | 201 | 0.160 |
Why?
|
Hearing Aids | 1 | 2019 | 34 | 0.160 |
Why?
|
Hearing | 1 | 2020 | 133 | 0.160 |
Why?
|
Diuretics | 1 | 2019 | 97 | 0.160 |
Why?
|
Cerebral Small Vessel Diseases | 1 | 2018 | 10 | 0.160 |
Why?
|
Time-to-Treatment | 1 | 2019 | 117 | 0.150 |
Why?
|
Postprandial Period | 1 | 2017 | 21 | 0.140 |
Why?
|
Treatment Outcome | 5 | 2021 | 7029 | 0.140 |
Why?
|
Tomography, X-Ray Computed | 4 | 2021 | 2324 | 0.140 |
Why?
|
Hearing Loss | 1 | 2019 | 154 | 0.140 |
Why?
|
Computed Tomography Angiography | 2 | 2017 | 424 | 0.140 |
Why?
|
Brain Ischemia | 1 | 2021 | 665 | 0.130 |
Why?
|
Atherosclerosis | 1 | 2017 | 204 | 0.120 |
Why?
|
Lipoproteins, LDL | 1 | 2017 | 343 | 0.120 |
Why?
|
Middle Aged | 9 | 2021 | 21147 | 0.100 |
Why?
|
Excitatory Amino Acid Antagonists | 1 | 2012 | 128 | 0.100 |
Why?
|
Ketamine | 1 | 2012 | 57 | 0.100 |
Why?
|
Antidepressive Agents | 1 | 2012 | 216 | 0.090 |
Why?
|
Disease Progression | 3 | 2020 | 1038 | 0.090 |
Why?
|
Prognosis | 3 | 2023 | 2093 | 0.090 |
Why?
|
Logistic Models | 3 | 2020 | 1420 | 0.090 |
Why?
|
Heart Failure | 1 | 2019 | 1180 | 0.090 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2019 | 1085 | 0.090 |
Why?
|
Male | 10 | 2023 | 37321 | 0.090 |
Why?
|
Bipolar Disorder | 1 | 2012 | 307 | 0.090 |
Why?
|
Female | 10 | 2023 | 38074 | 0.090 |
Why?
|
Adult | 4 | 2020 | 21403 | 0.080 |
Why?
|
Observer Variation | 2 | 2021 | 330 | 0.080 |
Why?
|
Image Processing, Computer-Assisted | 2 | 2021 | 689 | 0.070 |
Why?
|
Multivariate Analysis | 2 | 2020 | 1046 | 0.060 |
Why?
|
Double-Blind Method | 2 | 2023 | 1738 | 0.060 |
Why?
|
Alcoholism | 1 | 2012 | 1109 | 0.060 |
Why?
|
Linguistics | 1 | 2023 | 10 | 0.060 |
Why?
|
Sensitivity and Specificity | 2 | 2017 | 1753 | 0.050 |
Why?
|
Retrospective Studies | 3 | 2021 | 7277 | 0.050 |
Why?
|
Probability | 1 | 2022 | 245 | 0.050 |
Why?
|
Nimodipine | 1 | 2021 | 5 | 0.050 |
Why?
|
Language | 1 | 2023 | 120 | 0.050 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2021 | 58 | 0.050 |
Why?
|
Multicenter Studies as Topic | 1 | 2021 | 186 | 0.050 |
Why?
|
Cerebral Infarction | 1 | 2021 | 103 | 0.050 |
Why?
|
Automation | 1 | 2021 | 45 | 0.050 |
Why?
|
Bayes Theorem | 1 | 2022 | 307 | 0.050 |
Why?
|
Aged, 80 and over | 2 | 2021 | 4848 | 0.050 |
Why?
|
Magnetic Resonance Imaging | 2 | 2020 | 2223 | 0.040 |
Why?
|
Speech Reception Threshold Test | 1 | 2019 | 25 | 0.040 |
Why?
|
Audiometry, Pure-Tone | 1 | 2019 | 96 | 0.040 |
Why?
|
Computer Simulation | 1 | 2022 | 706 | 0.040 |
Why?
|
Mortality | 1 | 2020 | 163 | 0.040 |
Why?
|
Patient Care Planning | 1 | 2018 | 108 | 0.040 |
Why?
|
Glasgow Coma Scale | 1 | 2017 | 65 | 0.040 |
Why?
|
Calibration | 1 | 2017 | 73 | 0.040 |
Why?
|
White Matter | 1 | 2020 | 174 | 0.040 |
Why?
|
Iodine | 1 | 2017 | 42 | 0.040 |
Why?
|
Infant, Newborn | 1 | 2023 | 2455 | 0.040 |
Why?
|
Medicare | 1 | 2019 | 319 | 0.040 |
Why?
|
Infant | 1 | 2023 | 2891 | 0.030 |
Why?
|
Phantoms, Imaging | 1 | 2017 | 189 | 0.030 |
Why?
|
Magnetic Resonance Angiography | 1 | 2017 | 181 | 0.030 |
Why?
|
Case-Control Studies | 1 | 2020 | 1553 | 0.030 |
Why?
|
Reproducibility of Results | 1 | 2021 | 2077 | 0.030 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2017 | 507 | 0.030 |
Why?
|
Health Behavior | 1 | 2019 | 458 | 0.030 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2019 | 1745 | 0.030 |
Why?
|
Comorbidity | 1 | 2019 | 1426 | 0.030 |
Why?
|
Software | 1 | 2017 | 418 | 0.030 |
Why?
|
Risk Assessment | 1 | 2021 | 2007 | 0.030 |
Why?
|
Quality of Life | 1 | 2023 | 1515 | 0.030 |
Why?
|
Electrocardiography | 1 | 2017 | 601 | 0.030 |
Why?
|
Cohort Studies | 1 | 2019 | 2358 | 0.030 |
Why?
|
Valproic Acid | 1 | 2012 | 93 | 0.030 |
Why?
|
Infusions, Intravenous | 1 | 2012 | 334 | 0.030 |
Why?
|
Cross-Over Studies | 1 | 2012 | 260 | 0.030 |
Why?
|
Personality Inventory | 1 | 2012 | 197 | 0.020 |
Why?
|
Prospective Studies | 1 | 2019 | 3705 | 0.020 |
Why?
|
Linear Models | 1 | 2012 | 521 | 0.020 |
Why?
|
Time Factors | 1 | 2019 | 4655 | 0.020 |
Why?
|
Psychiatric Status Rating Scales | 1 | 2012 | 782 | 0.020 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2012 | 931 | 0.020 |
Why?
|
United States | 1 | 2019 | 7367 | 0.020 |
Why?
|
Brain | 1 | 2017 | 2176 | 0.020 |
Why?
|